within Pharmacolibrary.Drugs.ATC.J;

model J01DI03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.00017333333333333334,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.013699999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01DI03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Faropenem is an orally administered beta-lactam antibiotic belonging to the penem class, structurally related to carbapenems. It is primarily used to treat various bacterial infections, including respiratory tract, urinary tract, and skin infections. While not approved in the United States, it is available and used clinically in countries such as Japan and India.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Schurek, KN, et al., &amp; Zhanel, GG (2007). Faropenem: review of a new oral penem. <i>Expert review of anti-infective therapy</i> 5(2) 185–198. DOI:<a href=&quot;https://doi.org/10.1586/14787210.5.2.185&quot;>10.1586/14787210.5.2.185</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17402834/&quot;>https://pubmed.ncbi.nlm.nih.gov/17402834</a></p></li><li><p> (2008). Faropenem medoxomil: A0026, BAY 56-6854, BAY 566854, faropenem daloxate, SUN 208, SUN A0026. <i>Drugs in R&amp;D</i> 9(2) 115–124. DOI:<a href=&quot;https://doi.org/10.2165/00126839-200809020-00005&quot;>10.2165/00126839-200809020-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18298129/&quot;>https://pubmed.ncbi.nlm.nih.gov/18298129</a></p></li><li><p>Gurumurthy, M, et al., &amp; Paton, NI (2017). Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial. <i>The Journal of antimicrobial chemotherapy</i> 72(7) 2012–2019. DOI:<a href=&quot;https://doi.org/10.1093/jac/dkx081&quot;>10.1093/jac/dkx081</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28333342/&quot;>https://pubmed.ncbi.nlm.nih.gov/28333342</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01DI03;
